(P076) Stereotactic Body Radiation Therapy (SBRT) for the Primary Treatment of Localized Prostate Cancer

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

We report an update of our previously published experience for primary treatment of prostate cancer with CyberKnife SBRT, assessing efficacy and toxicity.

Matthew Bernetich, Luther W. Brady, MD, Rachelle Lanciano, MD, Jun Yang, PhD; Philadelphia CyberKnife; Crozer Keystone Healthcare System; Drexel University

Introduction: The American Society of Radiation Oncology (ASTRO) model policy update, published April 17, 2013, acknowledges that stereotactic body radiation therapy (SBRT) is equivalent to standard radiation modalities used to treat prostate cancer, such as intensity-modulated radiation therapy (IMRT). Furthermore, ASTRO supports the treatment of low- and intermediate-risk prostate cancer with SBRT, where it has excellent biochemical control rates with correspondingly low rates of severe toxicity. However, only recently have 5-year data been published, with a limited sample size. We report an update of our previously published experience for primary treatment of prostate cancer with CyberKnife SBRT, assessing efficacy and toxicity.

Methods: From 2007 to 2012, 143 localized prostate cancer patients were treated with primary SBRT using the CyberKnife system. Risk groups analyzed ranged from very low (20%) and low (24%) to intermediate (43%) and high (14%). Various dose levels were used over the years of treatment and, for the purpose of this study, have been categorized into low-dose (35 Gy, n = 5 or 36.25 Gy, n = 109) and high-dose (37.5 Gy, n = 30). All treatments were delivered in five fractions. Twenty-nine percent of the patients received androgen deprivation therapy, usually administered to intermediate- and high-risk patients.

Results: At a median follow-up time of 33 months, the median PSA value was 0.30 ng/mL. The 5-year freedom from biochemical failure (FFBF) was 94.1%, 93.9%, and 82.5% for very low–/low-, intermediate-, and high-risk patients, respectively. A dose response was observed between the low-dose and high-dose groups for all patients, with FFBF of 79.8% vs 100.0% (P = .0396), respectively, and for the combined group of intermediate- and high-risk patients, with FFBF of 87.6% vs 100.0% (P = .1255), respectively. Severe genitourinary (GU) toxicities included 2% acute and 3% late toxicities. No severe gastrointestinal toxicities were observed. At last follow-up, 12% of hormone-naive patients lost the ability to achieve erections strong enough for penetration and required erectile dysfunction (ED) medication for intercourse. No hormone-naive patient who was potent before SBRT developed ED refractory to medical treatment.

Conclusion: Our experience with CyberKnife SBRT for localized prostate cancer demonstrates favorable efficacy with less toxicity compared with the outcome for IMRT as reported in the literature.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Related Content